The new Clinerion patent underpins any medical EHR database infrastructure that incorporates a hybrid model of cloud-and-local server node installations at individual hospitals, as well as any method for search of patient cohort care metrics across such a platform. This allows real-time search at each individual hospital across the entire network at once, returning aggregate metrics from the entire network. 
Exscientia, a clinical-stage, artificial intelligence (AI)-driven pharmatech company, today announced that Bristol Myers Squibb has elected to in-license an immune-modulating drug candidate created by Exscientia. Exscientia has two active collaborations with Bristol Myers Squibb, which together focus on multiple therapeutic areas, including oncology and immunology. 
Abbott (NYSE: ABT) has received U.S. Food and Drug Administration (FDA) clearance for its latest optical coherence tomography (OCT) imaging platform powered by the company's new Ultreon Software. This innovative imaging software combines OCT with artificial intelligence (AI) to provide physicians an enhanced, comprehensive view of coronary blood flow and blockages to assist physician decision-making and provide the best pathway for treatment. 
Siemens Healthineers presents its second pathway for its AI-Pathway Companion(1) at the Healthcare Information and Management Systems Society Global Health Conference 2021 (HIMSS 21). This new pathway is focused on non-small cell lung cancer, supporting personalized and standardized decision-making along the whole treatment process(2). 
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced the introduction of two new Philips HealthSuite solutions that are secure, cloud-based and intended to break down barriers across patient care in a scalable, cost-effective model. 
Rapid integration of care services and secure data interchange has enabled Humber Teaching NHS Foundation Trust to embrace its EPR move to the cloud through Dedalus’ Healthcare Platform.
Humber Teaching NHS Foundation Trust, was the first NHS Trust to go live with the Dedalus Care Suite EPR and since moving to the cloud they have seen enhanced performance of the EPR.
Abbott announced today that the U.S. Food and Drug Administration (FDA) has cleared the FreeStyle® Libre 2 iOS application for use with compatible iPhones(1), providing a comprehensive digital offering for its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system. FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone every minute with optional real-time glucose alarms(2).